Breaking News, Collaborations & Alliances

Andelyn Biosciences Signs Licensing Agreement with Solid Biosciences

Non-exclusive license provides Solid’s proprietary, next-gen capsid, AAV-SLB101, to Andelyn Biosciences.

Author Image

By: Charlie Sternberg

Associate Editor

Andelyn Biosciences, a patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has entered a non-exclusive worldwide license and collaboration agreement with Solid Biosciences Inc., a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, for the use of Solid’s proprietary, next-generation capsid, AAV-SLB101. Under the terms of the agreement, Solid grants Andelyn a non-exclusive worldwide license to provid...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters